Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
10.1038/s41368-020-0084-8
- Author:
Zi MEI
1
;
Junwen HUANG
1
;
Bin QIAO
2
;
Alfred King-Yin LAM
3
Author Information
1. Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
2. Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. qiaobin@zzu.edu.cn.
3. Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. a.lam@griffith.edu.au.
- Publication Type:Journal Article
- MeSH:
Head and Neck Neoplasms;
pathology;
therapy;
Humans;
Immunologic Factors;
therapeutic use;
Immunotherapy;
methods;
Squamous Cell Carcinoma of Head and Neck;
pathology;
therapy;
Tumor Microenvironment
- From:
International Journal of Oral Science
2020;12(1):16-16
- CountryChina
- Language:English
-
Abstract:
With the understanding of the complex interaction between the tumour microenvironment and immunotherapy, there is increasing interest in the role of immune regulators in the treatment of head and neck squamous cell carcinoma (HNSCC). Activation of T cells and immune checkpoint molecules is important for the immune response to cancers. Immune checkpoint molecules include cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), T-cell immunoglobulin mucin protein 3 (TIM-3), lymphocyte activation gene 3 (LAG-3), T cell immunoglobin and immunoreceptor tyrosine-based inhibitory motif (TIGIT), glucocorticoid-induced tumour necrosis factor receptor (GITR) and V-domain Ig suppressor of T cell activation (VISTA). Many clinical trials using checkpoint inhibitors, as both monotherapies and combination therapies, have been initiated targeting these immune checkpoint molecules. This review summarizes the functional mechanism and use of various immune checkpoint molecules in HNSCC, including monotherapies and combination therapies, and provides better treatment options for patients with HNSCC.
